| 产品描述: | Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor |
| 靶点: |
EGFR;EGFR; BTK |
| 体外研究: |
Olmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.In addition, olmutinib at reversal concentration affected neither the protein expression level nor the localization of ABCG2.The results observed from the accumulation/efflux study of olmutinib showed that olmutinib reversed ABCG2-mediated MDR with an increasing intracellular drug accumulation due to inhibited drug efflux.We also had consistent results with the ATPase assay that olmutinib stimulated ATPase activity of ABCG2 up to 3.5-fold.Additionally, the molecular interaction between olmutinib and ABCG2 was identified by docking simulation.Olmutinib not only interacts directly with ABCG2 but also works as a competitive inhibitor of the transport protein |
| 参考文献: |
1. Zhang Z , Fu L , Guo X , et al. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATPbinding cassette subfamily G member 2 in vitro and in vivo[J]. 2018, 008(004):563-574. 2. Zhang W , Fan Y F , Cai C Y , et al. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells[J]. Frontiers in Pharmacology, 2018, 9. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.055 ml |
10.276 ml |
20.551 ml |
| 5 mM |
0.411 ml |
2.055 ml |
4.11 ml |
| 10 mM |
0.206 ml |
1.028 ml |
2.055 ml |
| 50 mM |
0.041 ml |
0.206 ml |
0.411 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |